Literature DB >> 17687153

Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings.

Philippe L Bedard1, Monika K Krzyzanowska, Melania Pintilie, Ian F Tannock.   

Abstract

PURPOSE: To investigate the prevalence of underpowered randomized controlled trials (RCTs) presented at American Society of Clinical Oncology (ASCO) annual meetings.
METHODS: We surveyed all two-arm phase III RCTs presented at ASCO annual meetings from 1995 to 2003 for which negative results were obtained. Post hoc calculations were performed using a power of 80% and an alpha level of .05 (two sided) to determine sample sizes required to detect small, medium, and large effect sizes. For studies reporting a proportion or time-to-event as primary end point, effect size was expressed as an odds ratio (OR) or hazard ratio (HR), respectively, with a small effect size defined as OR/HR >or= 1.3, medium effect size defined as OR/HR >or= 1.5, and large effect size defined as OR/HR >or= 2.0. Logistic regression was used to identify factors associated with lack of statistical power.
RESULTS: Of 423 negative RCTs for which post hoc sample size calculations could be performed, 45 (10.6%), 138 (32.6%), and 233 (55.1%) had adequate sample size to detect small, medium, and large effect sizes, respectively. Only 35 negative RCTs (7.1%) reported a reason for inadequate sample size. In a multivariable model, studies that were presented at oral sessions (P = .0038), multicenter studies supported by a cooperative group (P < .0001), and studies with time to event as primary outcome (P < .0001) were more likely to have adequate sample size.
CONCLUSION: More than half of negative RCTs presented at ASCO annual meetings do not have an adequate sample to detect a medium-size treatment effect.

Mesh:

Year:  2007        PMID: 17687153     DOI: 10.1200/JCO.2007.11.3670

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  19 in total

Review 1.  From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology.

Authors:  Kanwal Pratap Singh Raghav; Sminil Mahajan; James C Yao; Brian P Hobbs; Donald A Berry; Rebecca D Pentz; Alda Tam; Waun K Hong; Lee M Ellis; James Abbruzzese; Michael J Overman
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

2.  'Optimism bias' in contemporary national clinical trial network phase III trials: are we improving?

Authors:  Kaveh Zakeri; Sonal Noticewala; Lucas Vitzthum; E Sojourner; Hanjie Shen; Loren Mell
Journal:  Ann Oncol       Date:  2018-10-01       Impact factor: 32.976

3.  Patients' Perspectives on Integrating Acupuncture into the Radiation Oncology Setting.

Authors:  Eitan Frankel; Sheila Garland; Salimah H Meghani; Neha Vapiwala; Jun J Mao
Journal:  Eur J Integr Med       Date:  2014-10-01       Impact factor: 1.314

4.  Using pay for performance to improve treatment implementation for adolescent substance use disorders: results from a cluster randomized trial.

Authors:  Bryan R Garner; Susan H Godley; Michael L Dennis; Brooke D Hunter; Christin M L Bair; Mark D Godley
Journal:  Arch Pediatr Adolesc Med       Date:  2012-10

Review 5.  Optimism bias leads to inconclusive results-an empirical study.

Authors:  Benjamin Djulbegovic; Ambuj Kumar; Anja Magazin; Anneke T Schroen; Heloisa Soares; Iztok Hozo; Mike Clarke; Daniel Sargent; Michael J Schell
Journal:  J Clin Epidemiol       Date:  2010-12-16       Impact factor: 6.437

6.  Delta inflation: a bias in the design of randomized controlled trials in critical care medicine.

Authors:  Scott K Aberegg; D Roxanne Richards; James M O'Brien
Journal:  Crit Care       Date:  2010-04-29       Impact factor: 9.097

7.  Is it really self-control? Examining the predictive power of the delay of gratification task.

Authors:  Angela L Duckworth; Eli Tsukayama; Teri A Kirby
Journal:  Pers Soc Psychol Bull       Date:  2013-04-12

8.  Are surgical trials with negative results being interpreted correctly?

Authors:  Baruch A Brody; Carol M Ashton; Dandan Liu; Youxin Xiong; Xuan Yao; Nelda P Wray
Journal:  J Am Coll Surg       Date:  2012-11-22       Impact factor: 6.113

9.  Race/ethnicity, education, and treatment parameters as moderators and predictors of outcome in binge eating disorder.

Authors:  Heather Thompson-Brenner; Debra L Franko; Douglas R Thompson; Carlos M Grilo; Christina L Boisseau; James P Roehrig; Lauren K Richards; Susan W Bryson; Cynthia M Bulik; Scott J Crow; Michael J Devlin; Amy A Gorin; Jean L Kristeller; Robin Masheb; James E Mitchell; Carol B Peterson; Debra L Safer; Ruth H Striegel; Denise E Wilfley; G Terence Wilson
Journal:  J Consult Clin Psychol       Date:  2013-05-06

10.  Design analysis indicates Potential overestimation of treatment effects in randomized controlled trials supporting Food and Drug Administration cancer drug approvals.

Authors:  Emily M Lord; Isabelle R Weir; Ludovic Trinquart
Journal:  J Clin Epidemiol       Date:  2018-07-02       Impact factor: 6.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.